FDA UNTITLED_LETTER - Rxtra Solutions - August 25, 2020

FDA UNTITLED_LETTER for Rxtra Solutions on August 25, 2020. Product: Drugs. Access full analysis and detailed observations.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA UNTITLED_LETTER for Rxtra Solutions on August 25, 2020. Product: Drugs. Access full analysis and detailed observations.

Violation Codes

21 CFR 216.24

21 CFR 211

21 U.S.C. 501(a)(2)(B)

21 U.S.C. 355

21 CFR 210

21 CFR 216

21 U.S.C. 352(f)(1)

21 U.S.C. 351(a)(2)(B)

21 U.S.C. 355(a)

21 U.S.C. 353a

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Rxtra Solutions

Inspection Date

August 25, 2020

Product Type

Drugs

People

Craig W. Swanson (Deputy District Director)

ID: cb3f2c93-75e3-4dbb-bc90-93f0c5466c30

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox